SCHEDULE 13G/A: Frazier Life Sciences Funds Update Significant Passive Stake in Maze Therapeutics
Beneficial Ownership Report Amendment
Frazier Life Sciences and affiliated funds have filed an amended Schedule 13G, disclosing their updated passive beneficial ownership in Maze Therapeutics, Inc., with key individuals holding up to 9.4% of the common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. and its general partners (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 3,044,573 shares, representing 7.0% of Maze Therapeutics, Inc. common stock.
- Frazier Life Sciences Public Overage Fund, L.P. and its general partners (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 898,383 shares, representing 2.1% of Maze Therapeutics, Inc. common stock.
- Frazier Life Sciences X, L.P. and its general partners (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 66,677 shares, representing 0.2% of Maze Therapeutics, Inc. common stock.
- Frazier Life Sciences XI, L.P. and its general partners (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 119,367 shares, representing 0.3% of Maze Therapeutics, Inc. common stock.
- James N. Topper and Patrick J. Heron each beneficially own 4,129,000 shares, representing 9.4% of the class, through their shared voting and investment power across multiple Frazier Life Sciences funds.
- Albert Cha and James Brush each beneficially own 3,942,956 shares, representing 9.0% of the class, through their shared voting and investment power across Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences Public Overage Fund, L.P.
- Daniel Estes beneficially owns 119,367 shares, representing 0.3% of the class, through his shared voting and investment power over shares held by Frazier Life Sciences XI, L.P.
- The beneficial ownership percentages are calculated based on 43,796,057 shares of Common Stock outstanding as of March 25, 2025, as reported in Maze Therapeutics, Inc.'s Annual Report on Form 10-K.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or prospects. It is neutral.
Future Outlook
NA
Industry Context
This Schedule 13G/A filing is a routine disclosure by institutional investors, Frazier Life Sciences and its affiliated funds, updating their passive ownership stake in Maze Therapeutics, Inc., a biotechnology company. Such filings are standard practice for investors holding significant, non-controlling positions in publicly traded companies, providing transparency on major shareholder interests within the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes held by institutional investors and their principals, which can influence perceptions of stability and investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2016-03-29 | Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron. |
| 2017-07-31 | Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron. |
| 2021-08-16 | Power of Attorney filed with the SEC for Albert Cha and James Brush. |
| 2022-04-18 | Power of Attorney filed with the SEC for Daniel Estes. |
| 2025-03-25 | Date of common stock outstanding calculation (43,796,057 shares) as per Issuer's Annual Report on Form 10-K. |
| 2025-03-31 | Date of event which requires filing of this statement (also date of Issuer's Annual Report on Form 10-K filing). |
| 2025-04-29 | Date of filing of this Schedule 13G/A and Joint Filing Agreement. |
Keywords
SEC Filing, Schedule 13G/A, Beneficial Ownership, Maze Therapeutics Inc., Frazier Life Sciences, Institutional Investor, Passive Investment, Equity Holdings, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.